What is GlycanAge?
GlycanAge operates at the intersection of cutting-edge biotechnology and the burgeoning field of longevity science. The company specializes in glycobiology, the study of carbohydrates, and its application to understanding and measuring biological aging. Through its proprietary biological age test, GlycanAge provides individuals with a detailed assessment of their aging process, moving beyond chronological age to offer a more accurate reflection of their physiological state.
This innovative approach positions GlycanAge as a leader in personalized preventative healthcare, enabling users to make data-driven decisions to optimize their healthspan and well-being. The company's commitment to scientific rigor and accessible technology is paving the way for a future where proactive health management is the norm.
How much funding has GlycanAge raised?
GlycanAge has raised a total of $12.9M across 2 funding rounds:
Angel/Seed
$4.2M
Unspecified
$8.7M
Angel/Seed (2024): $4.2M with participation from LAUNCHub
Unspecified (2025): $8.7M led by BrightCap Ventures, Fifth Quarter Ventures, South Central Ventures, and Impetus Capital
Key Investors in GlycanAge
LAUNCHub
LAUNCHub is an early-stage venture capital fund that invests in startups from South-Eastern and Central-Eastern Europe, providing initial investments and strategic guidance to help companies raise significant follow-on funding.
BrightCap Ventures
BrightCap Ventures is an early-stage venture capital fund based in Sofia, specializing in investments in tech startups from Southeast Europe, partnering with global founders and providing access to a vast global network.
Fifth Quarter Ventures
Fifth Quarter Ventures is an early-stage venture capital fund focused on investing in startups from the Western Balkans, particularly in the Adriatic region, with a strong emphasis on sectors like AI, development tools, and crypto/Web3.
What's next for GlycanAge?
The substantial enterprise-level funding and recent strategic investment signal a strong market validation for GlycanAge's pioneering work in biological aging. This capital infusion is poised to fuel significant expansion, likely encompassing further research and development into advanced diagnostic tools, enhancement of their testing platform, and broader market penetration. GlycanAge is strategically positioned to capitalize on the growing global demand for personalized health solutions and preventative care.
The company's trajectory suggests a focus on scaling its operations, forging strategic partnerships within the healthcare and wellness industries, and potentially exploring new applications for its glycobiology expertise. This backing will be instrumental in solidifying GlycanAge's position as a key innovator in the longevity and personalized medicine sectors.
